EPIC-Spain: Higher Olive Oil Intake Linked to 26% Lower Mortality

This 13.4-year prospective cohort study from the European Prospective Investigation into Cancer and Nutrition (EPIC-Spain) tracked 40,622 Spanish adults to test whether higher olive oil intake was associated with lower overall and cause-specific mortality. Published in the American Journal of Clinical Nutrition, the analysis found that the highest quartile of olive oil consumption was linked to a 26% reduction in all-cause mortality and a 44% reduction in cardiovascular mortality, with no significant association for cancer mortality.

Why This Study Matters

By 2012, the link between olive oil and reduced cardiovascular disease risk was well established. What was missing was direct data on overall mortality -- the ultimate hard endpoint. Most cohort analyses had focused on disease incidence (heart attacks, strokes, cancers) rather than death from any cause, and the few mortality analyses available were either small or from non-Mediterranean populations where olive oil intake clusters with other health behaviors in ways that make confounding difficult to disentangle.

This analysis used the EPIC-Spain cohort -- 40,622 adults from five Spanish regions, recruited between 1992 and 1996 -- to ask the mortality question directly. The Mediterranean setting matters because olive oil is a culinary staple consumed across the socioeconomic spectrum, which reduces (though doesn't eliminate) the risk that olive oil consumption is just a marker for an overall health-conscious lifestyle.

The result was a clear and large effect: highest-quartile consumers had a 26% lower risk of dying from any cause and a 44% lower risk of dying from cardiovascular disease compared to non-consumers, over a median 13.4 years of follow-up.

How It Was Designed

The basics: 40,622 participants (62% female), aged 29 to 69 at recruitment, drawn from five Spanish regions (Asturias, Granada, Guipuzcoa, Murcia, Navarra). Median follow-up was 13.4 years, during which 1,915 deaths were recorded -- 416 from cardiovascular disease, 956 from cancer, and 417 from other causes.

Dietary intake was assessed at baseline using a validated computerized dietary history method -- a structured interview that captured habitual food intake over the past year, including specific olive oil intake. Participants were classified into quartiles of olive oil intake (energy-adjusted) and also analyzed as a continuous variable (per 10 g per 2,000 kcal per day).

Cox proportional-hazards models were adjusted for age, sex, BMI, waist-to-hip ratio, smoking status, education, physical activity, alcohol intake, total energy intake, and history of hypertension, diabetes, or hyperlipidemia at baseline. The non-consumer reference group included only participants who reported no olive oil intake at baseline -- a comparison that's only feasible in cohorts large enough to have a meaningful number of non-consumers, even in Spain.

Mortality outcomes were ascertained from regional and national mortality registries with ICD-10 cause-of-death coding. Cardiovascular mortality was defined as ICD-10 codes I00-I99; cancer mortality as C00-C97.

What They Found

Comparing the highest quartile of olive oil consumption to non-consumers, and modeling each 10 g/day increment in intake, the multivariable-adjusted hazard ratios were:

Outcome	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
All-cause mortality (Q4 vs. none)	0.74 (0.64-0.87)	26% lower	Death from any cause
CVD mortality (Q4 vs. none)	0.56 (0.40-0.79)	44% lower	Death from cardiovascular disease
Cancer mortality (Q4 vs. none)	Not significant	--	Death from any cancer
All-cause mortality (+10 g/day)	0.93 (0.90-0.97)	7% lower per 10 g	Continuous dose-response, all-cause
CVD mortality (+10 g/day)	0.87 (0.80-0.94)	13% lower per 10 g	Continuous dose-response, CVD

Green indicates a favorable direction. The all-cause and CVD mortality findings reached statistical significance both in the quartile comparison and the continuous dose-response. Cancer mortality showed no clear association.

Reading the Results

The findings group into three threads.

All-cause mortality (26% lower in the top quartile, 7% lower per 10 g/day). A 26% reduction is large for any single dietary exposure. The continuous dose-response (7% lower per 10 g/day, with a tight confidence interval of 0.90-0.97) is the more interpretable model: it tells you that the relationship is graded across the range of intake, not just a top-quartile effect. 10 g/day is roughly three-quarters of a tablespoon -- a moderate, achievable increment.

Cardiovascular mortality (44% lower in the top quartile, 13% lower per 10 g/day). This is the largest single effect in the analysis. It's consistent with the established mechanisms: olive oil polyphenols reduce oxidized LDL and CRP, the monounsaturated fat profile improves LDL/HDL ratios, and the overall pattern reduces blood pressure modestly. The 44% reduction is comparable in magnitude to PREDIMED's randomized signal for major cardiovascular events (30% reduction) -- not identical, but directionally aligned.

Cancer mortality (no significant association). This is worth being honest about. Despite a large sample and 956 cancer deaths, the analysis did not find a statistically significant association between olive oil intake and cancer mortality. That doesn't rule out an effect -- cancer is heterogeneous, and aggregating all cancers may mask site-specific effects -- but it does tell you the all-cause mortality signal is being driven almost entirely by cardiovascular outcomes, not by cancer prevention.

What Didn't Change

Olive oil intake was not significantly associated with cancer mortality in this cohort, even though the sample size was large enough to detect moderate effects. The signal for non-CVD, non-cancer mortality ("other causes") was also not statistically significant. The mortality benefit observed here is specifically a cardiovascular signal that propagates up to all-cause mortality because CVD is a major contributor to total deaths.

The study is observational, not interventional. It cannot prove causation. The multivariable adjustment reduces but does not eliminate residual confounding by overall diet quality, socioeconomic factors, or health-conscious behavior patterns. The Mediterranean setting helps -- olive oil isn't a luxury item in Spain -- but it doesn't remove the possibility entirely.

Broader Context

The EPIC-Spain mortality findings sit alongside other major cohort and trial evidence. PREDIMED (Spain, randomized) showed a 30% reduction in major cardiovascular events with a Mediterranean diet supplemented with extra virgin olive oil. The Harvard pooled cohort (Guasch-Ferre et al., 2022) showed a 19% reduction in cardiovascular mortality in a non-Mediterranean U.S. population. The Three-City Study (France) linked intensive olive oil use to lower stroke incidence and lower cognitive deficit risk in elderly populations.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at a daily intake of 5 mg of hydroxytyrosol and its derivatives. EPIC-Spain didn't measure polyphenol intake directly, but the continuous dose-response for cardiovascular mortality is consistent with the mechanistic pathway EFSA recognized.

What this cohort adds is the largest Spanish mortality analysis of olive oil to date, with a clean non-consumer reference group and a graded dose-response across the full range of intake.

Related Research

Continue exploring olive oil and polyphenol science:

• Olive Oil and 19% Lower Mortality in 92,383 U.S. Adults Over 28 Years
• Italian Cohort: Olive Oil Linked to Lower Cancer, CV and All-Cause Mortality
• Only Virgin Olive Oil -- Not Common -- Reduced Mortality in Spanish Cohort

Source: View the original study on PubMed

Olivea's Dosage

EPIC-Spain identified a 7% reduction in all-cause mortality and a 13% reduction in cardiovascular mortality per 10 g/day increment in olive oil intake. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.